For citations:
Zozulya N.I., Yastrubinetskaya O.I., Belyaeva S.S., Potapkova V.M., Davydkin I.L., Kurtov I.V., Shelekhova T.V., Evzerova Т.V., Gladilina О.G., Shcherbinina О.N., Volkova S.A., Maksimova А.S., Arkhipova N.V., Esefieva N.B., Smelyanskaya М.G., Molostvova V.Z., Kazankova T.A., Kirillova E.G., Chelnov V.G., Pospelova T.I., Babaeva T.N., Mamaev А.N., Momot А.P., Kosinova М.V., Shcherbakova N.V., Leshina О.А., Smirnova А.S., Korolenko Т.S., Kuchin А.А., Novoselov K.P., Bulieva N.B., Morozov S.V., Perina F.G., Kosacheva N.B., Safuanova G.Sh., Galina G.A., Yanturina N.Kh., Saitova А.R., Botvinovskiy V.E., Timofeeva M.A., Noskova E.V., Konyashina N.I., Schiller E.E., Shuster А.М., Kudlay D.А., Borozinets А.Yu. The results of the use of Octofactor in patients with moderate and severe hemophilia A (data from a prospective, multicenter, open-label, observational study). Russian Journal of Pediatric Hematology and Oncology. 2019;6(2):30-47. (In Russ.) https://doi.org/10.21682/2311-1267-2019-6-2-30-47
Email this article 